Topical Gentamicin 0.1% Promotes Collagen 7 Expression in Recessive Dystrophic Epidermolysis Bullosa

Area of Science:

• Dermatology
• Genetics
• Molecular Biology

Background:

• Epidermolysis bullosa (EB) is a group of rare genetic disorders with no current cure.
• Recessive dystrophic epidermolysis bullosa (RDEB) is characterized by mutations in the COL7A1 gene, leading to deficient type VII collagen.
• Aminoglycosides are being investigated for their potential to upregulate collagen 7 expression.

Purpose of the Study:

• To evaluate the efficacy of topical gentamicin in promoting collagen 7 expression in patients with dystrophic epidermolysis bullosa (DEB).
• To assess the safety and clinical impact of gentamicin treatment on skin lesions in DEB patients.

Main Methods:

• A 12-week study involving patients with DEB aged over 1 year.
• Application of 0.1% w/w gentamicin cream on one limb and standard dressings on the contralateral limb.
• Clinical evaluation of skin lesions and immunofluorescence antigen mapping (IFM) for collagen 7 at baseline and 12 weeks.

Main Results:

• Eight of twelve DEB patients completed the study.
• Significant increase in mean fluorescence intensity (MFI) of collagen 7 by 95.75% (P=0.06) after 12 weeks of gentamicin treatment.
• Greater collagen 7 expression increase observed in patients with known premature termination codon (PTC) mutations.
• No significant change in clinical severity (blisters, erosions, scarring) and no reported adverse effects.

Conclusions:

• Topical gentamicin 0.1% w/w is a safe and effective therapeutic option for increasing COL7A1 expression in DEB patients.
• Gentamicin is particularly beneficial for DEB patients carrying premature termination codon (PTC) mutations.
• Further research may explore long-term efficacy and broader applications in EB subtypes.